IRWD - Ironwood Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
15.11
+0.13 (+0.87%)
As of 2:22PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close14.98
Open15.12
Bid15.06 x 200
Ask15.08 x 200
Day's Range14.67 - 15.12
52 Week Range12.48 - 19.94
Volume523,156
Avg. Volume1,316,864
Market Cap2.26B
Beta1.47
PE Ratio (TTM)-15.48
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Short interest is high for IRWD with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting IRWD. Over the last month, growth of ETFs holding IRWD is favorable, with net inflows of $4.03 billion.

  • Capital Cube4 days ago

    Ironwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : October 16, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Ironwood Pharmaceuticals, Inc. a score of 47. Our analysis is based on comparing Ironwood Pharmaceuticals, Inc. with the following peers – Progenics Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Nektar Therapeutics, Astrazeneca PLC Sponsored ADR, Sucampo Pharmaceuticals, Inc. Class A, Cumberland Pharmaceuticals Inc. and Synthetic Biologics, Inc. (PGNX-US, SGYP-US, ... Read more (Read more...)

  • Capital Cube4 days ago

    ETFs with exposure to Ironwood Pharmaceuticals, Inc. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ironwood Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IRWD-US. Comparing the performance and risk of Ironwood Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : October 13, 2017
    Capital Cube7 days ago

    Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : October 13, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ironwood Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Don’t Miss Out On These Tantalizing Sohn Conference Stock Pitches
    Insider Monkey11 days ago

    Don’t Miss Out On These Tantalizing Sohn Conference Stock Pitches

    The Sohn and Next Wave Sohn Conferences took place in San Francisco last week, shining the spotlight on several growing and established hedge funds, who shared some of their best ideas with attendees. Last year’s event raised $320,000 for San Francisco’s underprivileged youth, providing them with educational opportunities. Among the hedge funds tracked by Insider […]

  • Capital Cube17 days ago

    ETFs with exposure to Ironwood Pharmaceuticals, Inc. : October 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ironwood Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IRWD-US. Comparing the performance and risk of Ironwood Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit18 days ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit22 days ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Capital Cube24 days ago

    Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : September 26, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ironwood Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Capital Cubelast month

    ETFs with exposure to Ironwood Pharmaceuticals, Inc. : September 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ironwood Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IRWD-US. Comparing the performance and risk of Ironwood Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
    Capital Cubelast month

    Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017

    Categories: Yahoo FinanceGet free summary analysis Ironwood Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Ironwood Pharmaceuticals, Inc. – Progenics Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Nektar Therapeutics, Astrazeneca PLC Sponsored ADR, Sucampo Pharmaceuticals, Inc. Class A, Cumberland Pharmaceuticals Inc. and Synthetic Biologics, Inc. ... Read more (Read more...)

  • Why Is Ironwood (IRWD) Down 4.1% Since the Last Earnings Report?
    Zacks2 months ago

    Why Is Ironwood (IRWD) Down 4.1% Since the Last Earnings Report?

    Ironwood (IRWD) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Ironwood Pharmaceuticals Inc NASDAQ/NGS:IRWD

  • Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe
    Zacks2 months ago

    Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe

    Key highlights include regulatory approvals for companies like Alexion (ALXN) and Ironwood while Biogen is one of the companies facing an investigation into the pricing of multiple sclerosis drugs.

  • Ironwood Pharma's Combination Gout Drug Gets FDA Approval
    Zacks2 months ago

    Ironwood Pharma's Combination Gout Drug Gets FDA Approval

    Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.

  • 24/7 Wall St.2 months ago

    Ironwood Pharma Muted Despite FDA Approval

    Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares remained relatively muted on Monday after the firm announced a key U.S. Food and Drug Administration (FDA) approval for its gout treatment duzallo. ...

  • TheStreet.com2 months ago

    Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

    The Cambridge, Mass.-based firm clinched FDA approval for hyperuricemia drug Duzallo.

  • Reuters2 months ago

    FDA approves Ironwood Pharma's gout drug

    Ironwood Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) approved its oral drug to treat a condition associated with gout. The company's once-daily drug, Duzallo, was approved to treat hyperuricemia — a condition characterized by too much uric acid in blood — in patients with gout, Ironwood said. Duzallo combines the standard of care treatment, allopurinol, with Ironwood's lesinurad to treat inefficient excretion and overproduction of uric acid in gout patients.

  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Ironwood Pharmaceuticals Inc NASDAQ/NGS:IRWD

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of IRWD earnings conference call or presentation 3-Aug-17 8:30pm GMT

    Q2 2017 Ironwood Pharmaceuticals Inc Earnings Call

  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on July 27. Over the last one-month, outflows of investor capital in ETFs holding IRWD totaled $507 million.

  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on July 27. Over the last one-month, outflows of investor capital in ETFs holding IRWD totaled $507 million.

  • Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up
    Zacks3 months ago

    Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up

    Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.

  • Associated Press3 months ago

    Ironwood reports 2Q loss

    The Cambridge, Massachusetts-based company said it had a loss of 30 cents per share. Losses, adjusted for non-recurring costs and amortization costs, were 28 cents per share. The results fell short of ...